MA
HSTO

MYDA Advisors’s Histogen Inc. Common Stock HSTO Stock Holding History

MYDA Advisors’s Portfolio HSTO Stock Details HSTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-180
Closed -$154K – 200
2018
Q2 		$154K Buy
+180
New +$149K 0.07% 128

Other funds holding HSTO

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

MYDA Advisors's HSTO Position: Q3 2018 in Review

MYDA Advisors sold out of Histogen Inc. Common Stock (HSTO) in Q3 2018, closing a stake of 180 shares — an estimated $154K sold.

MYDA Advisors first reported a position in HSTO in Q2 2018 and held it in 1 quarter. The position peaked at $154K in Q2 2018. 55 funds tracked by Wall St. Rank hold HSTO as of Q3 2018.

  • MYDA Advisors reported no remaining Histogen Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • MYDA Advisors sold 180 Histogen Inc. Common Stock shares in Q3 2018, an estimated $154K.
  • MYDA Advisors first reported a position in Histogen Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • MYDA Advisors's Histogen Inc. Common Stock position peaked at $154K in Q2 2018.
  • 55 funds tracked by Wall St. Rank held Histogen Inc. Common Stock as of Q3 2018.

Based on MYDA Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.